You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameParamethadione
Accession NumberDB00617  (APRD00236)
TypeSmall Molecule
GroupsApproved
DescriptionParamethadione is an anticonvulsant in the oxazolidinedione class. It is associated with fetal trimethadione syndrome, which is also known as paramethadione syndrome.
Structure
Thumb
Synonyms
Paradione
Parametadiona
Parametadione
Paramethadione
Paramethadionum
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIZ615FRW64N
CAS number115-67-3
WeightAverage: 157.1671
Monoisotopic: 157.073893223
Chemical FormulaC7H11NO3
InChI KeyVQASKUSHBVDKGU-UHFFFAOYSA-N
InChI
InChI=1S/C7H11NO3/c1-4-7(2)5(9)8(3)6(10)11-7/h4H2,1-3H3
IUPAC Name
5-ethyl-3,5-dimethyl-1,3-oxazolidine-2,4-dione
SMILES
CCC1(C)OC(=O)N(C)C1=O
Pharmacology
IndicationUsed for the control of absence (petit mal) seizures that are refractory to treatment with other medications.
Structured Indications Not Available
PharmacodynamicsParamethadione is an oxazolidinedione anticonvulsant similar to trimethadione that acts on the central nervous system (CNS) to reduce the number of absence seizures (often seen in epileptics). Absence seizures involve an interruption to consciousness where the person experiencing the seizure seems to become vacant and unresponsive for a short period of time (usually up to 30 seconds). Paramethadione acts on thalamic neurons in the thalamic reticular nucleus (which studies have shown to be associated with absence seizures, von Krosigk et al., 1993).
Mechanism of actionDione anticonvulsants such as paramethadione reduce T-type calcium currents in thalamic neurons (including thalamic relay neurons). This inhibits corticothalamic transmission and raises the threshold for repetitive activity in the thalamus. This results in a dampening of the abnormal thalamocortical rhythmicity proposed to underlie the 3-Hz spike-and-wave discharge seen on electroencephalogram (EEG) during absence seizures.
TargetKindPharmacological actionActionsOrganismUniProt ID
Voltage-dependent T-type calcium channel subunit alpha-1IProteinyes
suppressor
HumanQ9P0X4 details
Related Articles
AbsorptionRapid via the digestive tract.
Volume of distributionNot Available
Protein bindingNot significant
Metabolism

Primarily hepatic (mainly via cytochrome P450 isozyme 2C9), paramethadione is completely demethylated to 5-ethyl-5-methyl-2,4-oxazolidinedione, the active metabolite.

SubstrateEnzymesProduct
Paramethadione
5-ethyl-5-methyl-2,4-oxazolidinedioneDetails
Route of eliminationNot Available
Half life12 to 24 hours (however the half-life for the active metabolite is not known)
ClearanceNot Available
ToxicitySymptoms of overdose include clumsiness or unsteadiness, coma, severe dizziness, severe drowsiness, severe nausea, and problems with vision.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
AbirateroneThe serum concentration of Paramethadione can be increased when it is combined with Abiraterone.Approved
AmiodaroneThe metabolism of Paramethadione can be decreased when combined with Amiodarone.Approved, Investigational
AprepitantThe serum concentration of Paramethadione can be increased when it is combined with Aprepitant.Approved, Investigational
AtazanavirThe metabolism of Paramethadione can be decreased when combined with Atazanavir.Approved, Investigational
AtomoxetineThe metabolism of Paramethadione can be decreased when combined with Atomoxetine.Approved
BexaroteneThe serum concentration of Paramethadione can be decreased when it is combined with Bexarotene.Approved, Investigational
BoceprevirThe metabolism of Paramethadione can be decreased when combined with Boceprevir.Approved
BortezomibThe metabolism of Paramethadione can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Paramethadione can be decreased when it is combined with Bosentan.Approved, Investigational
CapecitabineThe metabolism of Paramethadione can be decreased when combined with Capecitabine.Approved, Investigational
CarbamazepineThe metabolism of Paramethadione can be increased when combined with Carbamazepine.Approved, Investigational
CelecoxibThe metabolism of Paramethadione can be decreased when combined with Celecoxib.Approved, Investigational
CeritinibThe serum concentration of Paramethadione can be increased when it is combined with Ceritinib.Approved
CholecalciferolThe metabolism of Paramethadione can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
ClarithromycinThe metabolism of Paramethadione can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Paramethadione can be decreased when combined with Clemastine.Approved
ClopidogrelThe metabolism of Paramethadione can be decreased when combined with Clopidogrel.Approved, Nutraceutical
ClotrimazoleThe metabolism of Paramethadione can be decreased when combined with Clotrimazole.Approved, Vet Approved
CobicistatThe metabolism of Paramethadione can be decreased when combined with Cobicistat.Approved
ConivaptanThe serum concentration of Paramethadione can be increased when it is combined with Conivaptan.Approved, Investigational
CrizotinibThe metabolism of Paramethadione can be decreased when combined with Crizotinib.Approved
CyclosporineThe metabolism of Paramethadione can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
Cyproterone acetateThe serum concentration of Paramethadione can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
DabrafenibThe serum concentration of Paramethadione can be decreased when it is combined with Dabrafenib.Approved
DarunavirThe metabolism of Paramethadione can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Paramethadione can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Paramethadione can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Paramethadione can be decreased when combined with Delavirdine.Approved
DexamethasoneThe serum concentration of Paramethadione can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DihydroergotamineThe metabolism of Paramethadione can be decreased when combined with Dihydroergotamine.Approved
DiltiazemThe metabolism of Paramethadione can be decreased when combined with Diltiazem.Approved
DisulfiramThe metabolism of Paramethadione can be decreased when combined with Disulfiram.Approved
DoxycyclineThe metabolism of Paramethadione can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe metabolism of Paramethadione can be decreased when combined with Dronedarone.Approved
EfavirenzThe serum concentration of Paramethadione can be decreased when it is combined with Efavirenz.Approved, Investigational
EnzalutamideThe serum concentration of Paramethadione can be decreased when it is combined with Enzalutamide.Approved
ErythromycinThe metabolism of Paramethadione can be decreased when combined with Erythromycin.Approved, Vet Approved
Eslicarbazepine acetateThe serum concentration of Paramethadione can be decreased when it is combined with Eslicarbazepine acetate.Approved
EtravirineThe serum concentration of Paramethadione can be decreased when it is combined with Etravirine.Approved
FelodipineThe metabolism of Paramethadione can be decreased when combined with Felodipine.Approved, Investigational
FloxuridineThe metabolism of Paramethadione can be decreased when combined with Floxuridine.Approved
FluconazoleThe metabolism of Paramethadione can be decreased when combined with Fluconazole.Approved
FluorouracilThe metabolism of Paramethadione can be decreased when combined with Fluorouracil.Approved
FluvastatinThe metabolism of Paramethadione can be decreased when combined with Fluvastatin.Approved
FluvoxamineThe metabolism of Paramethadione can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Paramethadione can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Paramethadione can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Paramethadione can be increased when combined with Fosphenytoin.Approved
Fusidic AcidThe serum concentration of Paramethadione can be increased when it is combined with Fusidic Acid.Approved
GemfibrozilThe metabolism of Paramethadione can be decreased when combined with Gemfibrozil.Approved
IdelalisibThe serum concentration of Paramethadione can be increased when it is combined with Idelalisib.Approved
ImatinibThe metabolism of Paramethadione can be decreased when combined with Imatinib.Approved
IndinavirThe metabolism of Paramethadione can be decreased when combined with Indinavir.Approved
IrbesartanThe metabolism of Paramethadione can be decreased when combined with Irbesartan.Approved, Investigational
IsavuconazoniumThe metabolism of Paramethadione can be decreased when combined with Isavuconazonium.Approved, Investigational
IsoniazidThe metabolism of Paramethadione can be decreased when combined with Isoniazid.Approved
IsradipineThe metabolism of Paramethadione can be decreased when combined with Isradipine.Approved
ItraconazoleThe metabolism of Paramethadione can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Paramethadione can be increased when it is combined with Ivacaftor.Approved
KetoconazoleThe metabolism of Paramethadione can be decreased when combined with Ketoconazole.Approved, Investigational
LapatinibThe metabolism of Paramethadione can be decreased when combined with Lapatinib.Approved, Investigational
LeflunomideThe metabolism of Paramethadione can be decreased when combined with Leflunomide.Approved, Investigational
LopinavirThe metabolism of Paramethadione can be decreased when combined with Lopinavir.Approved
LosartanThe metabolism of Paramethadione can be decreased when combined with Losartan.Approved
LovastatinThe metabolism of Paramethadione can be decreased when combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Paramethadione can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Paramethadione can be increased when it is combined with Lumacaftor.Approved
MefloquineThe therapeutic efficacy of Paramethadione can be decreased when used in combination with Mefloquine.Approved
MianserinThe therapeutic efficacy of Paramethadione can be decreased when used in combination with Mianserin.Approved
MifepristoneThe serum concentration of Paramethadione can be increased when it is combined with Mifepristone.Approved, Investigational
MitotaneThe serum concentration of Paramethadione can be decreased when it is combined with Mitotane.Approved
ModafinilThe serum concentration of Paramethadione can be decreased when it is combined with Modafinil.Approved, Investigational
NafcillinThe serum concentration of Paramethadione can be decreased when it is combined with Nafcillin.Approved
NefazodoneThe metabolism of Paramethadione can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Paramethadione can be decreased when combined with Nelfinavir.Approved
NetupitantThe serum concentration of Paramethadione can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Paramethadione can be increased when combined with Nevirapine.Approved
NicardipineThe metabolism of Paramethadione can be decreased when combined with Nicardipine.Approved
NicotineThe metabolism of Paramethadione can be decreased when combined with Nicotine.Approved
NilotinibThe metabolism of Paramethadione can be decreased when combined with Nilotinib.Approved, Investigational
OlaparibThe metabolism of Paramethadione can be decreased when combined with Olaparib.Approved
OmeprazoleThe metabolism of Paramethadione can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
OrlistatThe serum concentration of Paramethadione can be decreased when it is combined with Orlistat.Approved, Investigational
OsimertinibThe serum concentration of Paramethadione can be increased when it is combined with Osimertinib.Approved
PalbociclibThe serum concentration of Paramethadione can be increased when it is combined with Palbociclib.Approved
PentobarbitalThe metabolism of Paramethadione can be increased when combined with Pentobarbital.Approved, Vet Approved
PhenobarbitalThe metabolism of Paramethadione can be increased when combined with Phenobarbital.Approved
PhenytoinThe metabolism of Paramethadione can be increased when combined with Phenytoin.Approved, Vet Approved
PioglitazoneThe metabolism of Paramethadione can be decreased when combined with Pioglitazone.Approved, Investigational
PosaconazoleThe metabolism of Paramethadione can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PrimidoneThe metabolism of Paramethadione can be increased when combined with Primidone.Approved, Vet Approved
PyrimethamineThe metabolism of Paramethadione can be decreased when combined with Pyrimethamine.Approved, Vet Approved
QuinineThe metabolism of Paramethadione can be decreased when combined with Quinine.Approved
RabeprazoleThe metabolism of Paramethadione can be decreased when combined with Rabeprazole.Approved, Investigational
RanolazineThe metabolism of Paramethadione can be decreased when combined with Ranolazine.Approved, Investigational
RifabutinThe metabolism of Paramethadione can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Paramethadione can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Paramethadione can be increased when combined with Rifapentine.Approved
RitonavirThe metabolism of Paramethadione can be decreased when combined with Ritonavir.Approved, Investigational
RosiglitazoneThe metabolism of Paramethadione can be decreased when combined with Rosiglitazone.Approved, Investigational
SaquinavirThe metabolism of Paramethadione can be decreased when combined with Saquinavir.Approved, Investigational
SecobarbitalThe metabolism of Paramethadione can be increased when combined with Secobarbital.Approved, Vet Approved
SildenafilThe metabolism of Paramethadione can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Paramethadione can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Paramethadione can be increased when it is combined with Simeprevir.Approved
SorafenibThe metabolism of Paramethadione can be decreased when combined with Sorafenib.Approved, Investigational
St. John's WortThe serum concentration of Paramethadione can be decreased when it is combined with St. John's Wort.Nutraceutical
StiripentolThe serum concentration of Paramethadione can be increased when it is combined with Stiripentol.Approved
SulfadiazineThe metabolism of Paramethadione can be decreased when combined with Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleThe metabolism of Paramethadione can be decreased when combined with Sulfamethoxazole.Approved
SulfisoxazoleThe metabolism of Paramethadione can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
TamoxifenThe metabolism of Paramethadione can be decreased when combined with Tamoxifen.Approved
TelaprevirThe metabolism of Paramethadione can be decreased when combined with Telaprevir.Approved
TelithromycinThe metabolism of Paramethadione can be decreased when combined with Telithromycin.Approved
TeriflunomideThe metabolism of Paramethadione can be decreased when combined with Teriflunomide.Approved
TicagrelorThe metabolism of Paramethadione can be decreased when combined with Ticagrelor.Approved
TiclopidineThe metabolism of Paramethadione can be decreased when combined with Ticlopidine.Approved
TocilizumabThe serum concentration of Paramethadione can be decreased when it is combined with Tocilizumab.Approved
TolbutamideThe metabolism of Paramethadione can be decreased when combined with Tolbutamide.Approved
TrimethoprimThe metabolism of Paramethadione can be decreased when combined with Trimethoprim.Approved, Vet Approved
Valproic AcidThe metabolism of Paramethadione can be decreased when combined with Valproic Acid.Approved, Investigational
ValsartanThe metabolism of Paramethadione can be decreased when combined with Valsartan.Approved, Investigational
VenlafaxineThe metabolism of Paramethadione can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Paramethadione can be decreased when combined with Verapamil.Approved
VoriconazoleThe metabolism of Paramethadione can be decreased when combined with Voriconazole.Approved, Investigational
ZafirlukastThe metabolism of Paramethadione can be decreased when combined with Zafirlukast.Approved, Investigational
ZiprasidoneThe metabolism of Paramethadione can be decreased when combined with Ziprasidone.Approved
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General References
  1. Hoffman DJ, Chun AH: Paramethadione and metabolite serum levels in humans after a single oral paramethadione dose. J Pharm Sci. 1975 Oct;64(10):1702-3. [PubMed:1185541 ]
  2. Feldman GL, Weaver DD, Lovrien EW: The fetal trimethadione syndrome: report of an additional family and further delineation of this syndrome. Am J Dis Child. 1977 Dec;131(12):1389-92. [PubMed:412416 ]
External Links
ATC CodesN03AC01
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9955
Blood Brain Barrier+0.9804
Caco-2 permeable+0.5334
P-glycoprotein substrateNon-substrate0.8117
P-glycoprotein inhibitor INon-inhibitor0.5232
P-glycoprotein inhibitor IINon-inhibitor0.5937
Renal organic cation transporterNon-inhibitor0.9572
CYP450 2C9 substrateNon-substrate0.8651
CYP450 2D6 substrateNon-substrate0.8869
CYP450 3A4 substrateSubstrate0.5517
CYP450 1A2 substrateNon-inhibitor0.8174
CYP450 2C9 inhibitorNon-inhibitor0.812
CYP450 2D6 inhibitorNon-inhibitor0.914
CYP450 2C19 inhibitorNon-inhibitor0.7845
CYP450 3A4 inhibitorNon-inhibitor0.8711
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8976
Ames testNon AMES toxic0.7081
CarcinogenicityNon-carcinogens0.8298
BiodegradationNot ready biodegradable0.8515
Rat acute toxicity2.2682 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9921
hERG inhibition (predictor II)Non-inhibitor0.9752
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Abbott laboratories pharmaceutical products div
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateLiquid
Experimental Properties
PropertyValueSource
boiling point101.5 °CNot Available
water solubility8.4 mg/mLNot Available
logP0.3Not Available
Predicted Properties
PropertyValueSource
Water Solubility135.0 mg/mLALOGPS
logP0.9ALOGPS
logP1.03ChemAxon
logS-0.07ALOGPS
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area46.61 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity37.72 m3·mol-1ChemAxon
Polarizability15.39 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (7.42 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-0006-9300000000-5b8273da08cb63d81fcfView in MoNA
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as oxazolidinediones. These are compounds containing an oxazolidine ring which bears two ketones.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassAzolidines
Sub ClassOxazolidines
Direct ParentOxazolidinediones
Alternative Parents
Substituents
  • Oxazolidinedione
  • Tertiary amine
  • Carboxamide group
  • Oxacycle
  • Azacycle
  • Monocarboxylic acid or derivatives
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aliphatic heteromonocyclic compound
Molecular FrameworkAliphatic heteromonocyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
suppressor
General Function:
Voltage-gated calcium channel activity
Specific Function:
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. Isoform alpha-1I gives rise to T-type calcium currents. T-type calcium channels belong to the "low-volta...
Gene Name:
CACNA1I
Uniprot ID:
Q9P0X4
Molecular Weight:
245100.8 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic or carcinogenic forms.
Gene Name:
CYP2E1
Uniprot ID:
P05181
Molecular Weight:
56848.42 Da
References
  1. Kurata N, Nishimura Y, Iwase M, Fischer NE, Tang BK, Inaba T, Yasuhara H: Trimethadione metabolism by human liver cytochrome P450: evidence for the involvement of CYP2E1. Xenobiotica. 1998 Nov;28(11):1041-7. [PubMed:9879636 ]
  2. Tanaka E, Terada M, Misawa S: Cytochrome P450 2E1: its clinical and toxicological role. J Clin Pharm Ther. 2000 Jun;25(3):165-75. [PubMed:10886461 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Tanaka E, Kurata N, Yasuhara H: Involvement of cytochrome P450 2C9, 2E1 and 3A4 in trimethadione N-demethylation in human microsomes. J Clin Pharm Ther. 2003 Dec;28(6):493-6. [PubMed:14651673 ]
  2. Kurata N, Nishimura Y, Iwase M, Fischer NE, Tang BK, Inaba T, Yasuhara H: Trimethadione metabolism by human liver cytochrome P450: evidence for the involvement of CYP2E1. Xenobiotica. 1998 Nov;28(11):1041-7. [PubMed:9879636 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Tanaka E, Kurata N, Yasuhara H: Involvement of cytochrome P450 2C9, 2E1 and 3A4 in trimethadione N-demethylation in human microsomes. J Clin Pharm Ther. 2003 Dec;28(6):493-6. [PubMed:14651673 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Kurata N, Nishimura Y, Iwase M, Fischer NE, Tang BK, Inaba T, Yasuhara H: Trimethadione metabolism by human liver cytochrome P450: evidence for the involvement of CYP2E1. Xenobiotica. 1998 Nov;28(11):1041-7. [PubMed:9879636 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23